Loading…
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $54M | $-467M | $-413M | $-387M | -34.6% | 48.0% | -161.3% |
| 2024 | $36M | $-420M | $674M | $-392M | 43.7% | 36.1% | - |
| 2023 | $27M | $-385M | $-352M | $-315M | -43.4% | 88.4% | - |
| 2022 | $14M | $-380M | $-232M | $-314M | -21.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 14.24 | 26.82 | 36.50 | 54.03 |
| Cost Of Revenue | 1.70 | 2.88 | 4.17 | 6.34 |
| Gross Profit | 12.54 | 23.94 | 32.33 | 47.68 |
| Operating Expense | 401.58 | 415.43 | 458.07 | 519.82 |
| Operating Income | -389.05 | -391.49 | -425.74 | -472.13 |
| EBITDA | -380.48 | -384.86 | -420.08 | -466.95 |
| EBIT | -389.05 | -391.49 | -425.74 | -472.13 |
| Pretax Income | -231.80 | -352.09 | 717.97 | -413.80 |
| Tax Provision | 0 | 0 | 44.24 | -1.02 |
| Net Income | -231.80 | -352.09 | 673.73 | -412.78 |
| Net Income Common Stockholders | -231.80 | -352.09 | 673.73 | -412.78 |
| Total Expenses | 403.29 | 418.31 | 462.24 | 526.16 |
| Interest Income | 12.79 | 33.34 | 48.08 | 56.38 |
| Research And Development | 279.91 | 295.53 | 301.29 | 339.54 |
| Selling General And Administration | 121.67 | 119.90 | 156.78 | 180.28 |
| Normalized EBITDA | -518.19 | -384.86 | -1,509.22 | -466.95 |
| Normalized Income | -369.50 | -352.09 | -348.29 | -412.78 |
| Basic EPS | -4.23 | -6.33 | 11.86 | -7.12 |
| Diluted EPS | -4.23 | -6.33 | 11.64 | -7.12 |
| Tax Effect Of Unusual Items | 0 | 0 | 67.12 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.06 | 0 |
| Total Unusual Items | 137.70 | 0 | 1,089.14 | 0 |
| Total Unusual Items Excluding Goodwill | 137.70 | 0 | 1,089.14 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -231.80 | -352.09 | 673.73 | -412.78 |
| Reconciled Depreciation | 8.56 | 6.62 | 5.65 | 5.18 |
| Reconciled Cost Of Revenue | 1.70 | 2.88 | 4.17 | 6.34 |
| Net Interest Income | 12.79 | 33.34 | 48.08 | 56.38 |
| Net Income From Continuing And Discontinued Operation | -231.80 | -352.09 | 673.73 | -412.78 |
| Total Operating Income As Reported | -389.05 | -391.49 | -425.74 | -472.13 |
| Diluted Average Shares | 54.79 | 55.65 | 57.89 | 57.97 |
| Basic Average Shares | 54.79 | 55.65 | 56.81 | 57.97 |
| Diluted NI Availto Com Stockholders | -231.80 | -352.09 | 673.73 | -412.78 |
| Net Income Including Noncontrolling Interests | -231.80 | -352.09 | 673.73 | -412.78 |
| Net Income Discontinuous Operations | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -231.80 | -352.09 | 673.73 | -412.78 |
| Other Income Expense | 144.45 | 6.05 | 1,095.62 | 1.96 |
| Other Non Operating Income Expenses | 6.75 | 6.05 | 6.49 | 1.96 |
| Special Income Charges | 137.70 | 0 | 1,089.14 | 0 |
| Gain On Sale Of Business | 137.70 | 0 | 1,089.14 | 0 |
| Restructuring And Mergern Acquisition | -127.85 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 12.79 | 33.34 | 48.08 | 56.38 |
| Total Other Finance Cost | -12.79 | 0 | 0 | 0 |
| Interest Income Non Operating | 12.79 | 33.34 | 48.08 | 56.38 |
| Operating Revenue | 14.24 | 26.82 | 36.50 | 54.03 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc.this co. | AGIO | $1.7B | - | 1.37 | -34.6% | -1.37 |
| Palvella Therapeutics, Inc. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Recursion Pharmaceuticals, Inc. | RXRX | $1.7B | - | 1.54 | -57.0% | -1.91 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.7B | - | 5.62 | -47.4% | -9.25 |
| Nurix Therapeutics, Inc. | NRIX |
| $1.7B |
| - |
| 3.57 |
| -49.1% |
| -4.02 |
| Sionna Therapeutics, Inc. | SION | $1.7B | - | 5.46 | -24.5% | -16.50 |
| Astrana Health, Inc. | ASTH | $1.6B | 83.54 | 2.41 | 2.9% | 18.68 |
| Healthcare Services Group, Inc. | HCSG | $1.6B | 26.18 | 3.03 | 11.6% | 16.59 |
| Innoviva, Inc. | INVA | $1.6B | 6.44 | 1.49 | 23.1% | 3.96 |
| Peer Median | - | 26.18 | 3.30 | -36.0% | -1.91 | |